Long-term Study With Trazodone Once-a-Day

  • End date
    Jun 30, 2022
  • participants needed
  • sponsor
    Aziende Chimiche Riunite Angelini Francesco S.p.A
Updated on 30 October 2021
psychiatric disorder
major depressive disorder


The aim of the present observational study is to assess the clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who demonstrated an initial positive response to the acute treatment with Trazodone once-a-day monotherapy, for up to 24 weeks.


This is an observational, prospective, single group, multicentre, international study.

The present study is planned to assess, in a real-world setting, the long-term clinical response, functional impairment and quality of life in outpatients with Major Depressive Disorder who, according to the physician's judgment, have responded to the acute monotherapy (6 to 8 weeks of treatment) with Trazodone once-a-day and are eligible to continue Trazodone once-a-day monotherapy according to clinical practice.

Condition Endogenous depression, Major depression, major depressive disorders, major depressive disorder
Treatment TraZODone Hydrochloride 300 MG
Clinical Study IdentifierNCT04295941
SponsorAziende Chimiche Riunite Angelini Francesco S.p.A
Last Modified on30 October 2021


Yes No Not Sure

Inclusion Criteria

Male and female patients of any ethnic origin 18 years old at Baseline
Outpatients who meet the Diagnostic and Statistical Manual of Mental Disorders
(DSM)-5 or the International Classification of Diseases (ICD)-10 criteria for
MDD as their primary diagnosis and presenting with an episode of MDD
Patients judged as responders to the acute monotherapy with TzOAD after a
minimum of 6 and a maximum of 8 weeks of treatment and who are eligible to
continue the assigned monotherapy according to the physician's judgement
Patients legally capable of giving their written consent for participation in
the study and for personal data processing and willing to comply with all
study procedures

Exclusion Criteria

Patients that meet any of the contraindications to the administration of TzOAD
according to the approved SmPC
Patients with previous or current diagnosis of bipolar disorder, schizophrenia
or other psychotic disorder, dysthymic or adjustment disorders, mental
retardation, organic mental disorders or mental disorders due to a general
medical condition
Patients with previous or current history of a clinically significant
neurological disorder, or any neurodegenerative diseases that might compromise
the participation in the study
Patients who are, according to the physician's judgement, at serious risk of
Patients with substance abuse or dependence (except nicotine dependence), as
defined by DSM-5
Patients participating in any pharmacological or non-pharmacological
interventional study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note